Micron shares plunge on weak second-quarter guidance

Micron shares plunge on weak second-quarter guidance


Sanjay Mehrotra, CEO of Micron Technology Inc., speaks during an interview with CNBC on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26, 2024. 

Brendan Mcdermid | Reuters

Micron shares plunged 13% in extended trading on Wednesday after the chipmaker issued weak second-quarter guidance despite an earnings beat for the latest period.

Here’s how the company did compared to analysts’ expectations surveyed by LSEG:

  • Earnings per share: $1.79, adjusted vs. $1.75 expected
  • Revenue: $8.71 billion vs. $8.71 billion expected

For the second quarter, Micron said it expects revenue of $7.9 billion, plus or minus $200 million, and adjusted earnings per share of $1.43, plus or minus 10 cents. Analysts were expecting revenue of $8.98 billion and EPS of $1.91, according to LSEG.

The computer memory and storage company has seen its shares climb 22% year to date as of market close, trailing the Nasdaq’s 29% gain. In the earnings report, Micron highlighted data centers and artificial intelligence ventures with Nvidia’s processors as growth areas.

“While consumer-oriented markets are weaker in the near term, we anticipate a return to growth in the second half of our fiscal year, said CEO Sanjay Mehrotra in a press release. “We continue to gain share in the highest margin and strategically important parts of the market and are exceptionally well positioned to leverage AI-driven growth to create substantial value for all stakeholders.”

WATCH: Micron shares continue to slip on guidance

Micron shares continue to slip on weaker-than-expected guidance



Source

Merck shells out  billion for London-based lung therapy firm Verona
World

Merck shells out $10 billion for London-based lung therapy firm Verona

Bloomberg | Bloomberg | Getty Images Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm’s respiratory treatment portfolio in a bid to diversify its revenue source beyond blockbuster cancer drug. Merck has been leaning on its aging cancer immunotherapy Keytruda, the world’s top-selling prescription medicine, […]

Read More
Singapore state investor Temasek is rethinking defense as a strategic ESG bet
World

Singapore state investor Temasek is rethinking defense as a strategic ESG bet

Defense stocks are booming — and according to one of Asia’s biggest investors, allocating capital to the sector doesn’t mean having to abandon ESG initiatives. Speaking to CNBC’s Martin Soong on Wednesday, Rohit Sipahimalani, chief investment officer at Singapore’s state investment fund Temasek, said his team were looking at opportunities in the European defense sector. […]

Read More
Shares of Ray-Ban maker EssilorLuxottica jump 6% on reported Meta stake in AI push
World

Shares of Ray-Ban maker EssilorLuxottica jump 6% on reported Meta stake in AI push

Smart Ray-Ban Glasses, on June 16, 2024, in Caen, Normandy, France. Nurphoto | Getty Images Shares of Ray-Ban maker EssilorLuxottica almost 6% on Wednesday on reports that Meta has taken a minority stake in the company amid growing appetite for AI-powered wearable devices. Meta reportedly bought a stake worth around 3 billion euros ($3.51 billion) […]

Read More